Related Research Articles
Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. Around 10% of latent infections progress to active disease which, if left untreated, kill about half of those affected. Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss. Infection of other organs can cause a wide range of symptoms.
Tuberculosis management describes the techniques and procedures utilized for treating tuberculosis (TB) or simply a treatment plan for TB.
Latent tuberculosis (LTB), also called latent tuberculosis infection (LTBI) is when a person is infected with Mycobacterium tuberculosis, but does not have active tuberculosis (TB). Active tuberculosis can be contagious while latent tuberculosis is not, and it is therefore not possible to get TB from someone with latent tuberculosis. The main risk is that approximately 10% of these people will go on to develop active tuberculosis. This is particularly true, and there is added risk, in particular situations such as medication that suppresses the immune system or advancing age.
TB Alliance is a not-for-profit product development partnership (PDP) dedicated to the discovery and development of new, faster-acting and affordable tuberculosis (TB) medicines. Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest pipeline of new TB drugs in history. It was founded in Cape Town, South Africa, and has since expanded. It is headquartered in New York City and has a regional office in Pretoria.
Extensively drug-resistant tuberculosis (XDR-TB) is a form of tuberculosis caused by bacteria that are resistant to some of the most effective anti-TB drugs. XDR-TB strains have arisen after the mismanagement of individuals with multidrug-resistant TB (MDR-TB).
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).
The National Tuberculosis Elimination Programme (NTEP), earlier known as the Revised National Tuberculosis Control Programme (RNTCP), is the Public Health initiative of the Government of India that organizes its anti-Tuberculosis efforts. It functions as a flagship component of the National Health Mission (NHM) and provides technical and managerial leadership to anti-tuberculosis activities in the country. As per the National Strategic Plan 2017–25, the program has a vision of achieving a "TB free India",with a strategies under the broad themes of "Prevent, Detect,Treat and Build pillars for universal coverage and social protection". The program provides, various free of cost, quality tuberculosis diagnosis and treatment services across the country through the government health system.
Bedaquiline, sold under the brand name Sirturo, is a medication used to treat active tuberculosis. Specifically, it is used to treat multi-drug-resistant tuberculosis (MDR-TB) along with other medications for tuberculosis. It is used by mouth.
Pretomanid is an antibiotic medication used for the treatment of multi-drug-resistant tuberculosis affecting the lungs. It is generally used together with bedaquiline and linezolid. It is taken by mouth.
Anand Grover is a senior lawyer known for legal activism in Indian law relating to homosexuality and HIV. Along with his wife Indira Jaising, he is a founder-member of the Lawyers Collective. He was the United Nations Special Rapporteur on the right to health from August 2008 to July 2014. He is currently and acting member of the Global Commission on Drug Policy.
Tuberculosis in India is a major health problem, causing about 220,000 deaths every year. In 2020, the Indian government made statements to eliminate tuberculosis from the country by 2025 through its National TB Elimination Program. Interventions in this program include major investment in health care, providing supplemental nutrition credit through the Nikshay Poshan Yojana, organizing a national epidemiological survey for tuberculosis, and organizing a national campaign to tie together the Indian government and private health infrastructure for the goal of eliminating the disease.
Operation ASHA(OpASHA) is a non-profit organization (NGO) founded in 2006 to bring tuberculosis (TB) treatment at economically feasible rates to disadvantaged communities. The organization's primary work is to detect and cure TB, as well as to prevent and treat multidrug-resistant tuberculosis (MDR-TB) in India and Cambodia. Operation ASHA specializes in last-mile connectivity, bridging the gap between government medicine distribution centers and the communities of patients to deliver treatment at the doorsteps of the under-served. In addition to detecting and curing TB, OpASHA's community health workers also educate the community about TB and its symptoms thereby helping to reduce the stigma there is regarding the disease. In addition to TB, Operation ASHA's model and technology has been used in many other diseases such as diabetes, hemophilia and mental health.
Prisons in Russia consist of four types of facilities: pre-trial institutions; educative or juvenile colonies; corrective colonies; and prisons.
The Indian hospitals were racially segregated hospitals, originally serving as tuberculosis sanatoria but later operating as general hospitals for indigenous peoples in Canada which operated during the 20th century. The hospitals were originally used to isolate Indigenous tuberculosis patients from the general population because of a fear among health officials that "Indian TB" posed a danger to the non-indigenous population. Many of these hospitals were located on Indian reserves, and might also be called reserve hospitals, while others were in nearby cities.
Delamanid, sold under the brand name Deltyba, is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
Anil Koul is a scientist and former Director of the CSIR-Institute of Microbial Technology (IMTECH), a premier biomedical and biotechnology research institution under Council of Scientific and Industrial Research (CSIR) under Ministry of Science and Technology, Govt. of India.
Zarir Udwadia is an Indian pulmonologist and researcher. His work on drug resistant tuberculosis has led to improvements in India's National Tuberculosis Control Programme. Udwadia was the only Indian invited by the WHO to be part of the TB ‘Guidelines Group’, which formulated the 4th edition of the TB Guidelines, published in 2010. He was also the only doctor to be named among India's best strategists.
Jaime Bayona García is a Peruvian physician who focuses on public health and he has become a specialist in studying the epidemiology of tuberculosis. He is also known for his case studies on HIV/AIDS in Peru and other developing countries. Dr. Bayona has also done work on how public health systems should improve, in terms of providing the best approach to help the sick that cannot afford health care.
Phumeza Tisile is a healthcare activist from South Africa who advocates for making tuberculosis medication inexpensive and widely available. Tisile survived extensively drug-resistant tuberculosis (XDR-TB), enduring three years and 8 months of treatment. Tisile's initial misdiagnoses led to months of incorrect treatment, which caused her to become deaf. As an activist, Tisile advocates for improved access to tuberculosis (TB) diagnosis and treatment, improved counseling for patients, research into better treatments, and elimination of TB stigma.
References
- 1 2 Amrit Dhillon (13 January 2017). "Politics and protocol leave Indian teen's life in the balance pending TB drug ruling". The Guardian.
- ↑ Shaikh-Lesko, Rina (January 19, 2017). "A Teen's Family Fought To Get Her A Restricted TB Drug — And Won". NPR.
- 1 2 3 Jennifer Furin (30 March 2019). "TB Killed Shreya Tripathi, But Her Death Could Have Been Avoided". The Wire.
- 1 2 Stephen Lewis and Jennifer Furin (24 March 2019). "India should heed a teenager's historic fight for lifesaving tuberculosis treatment". Stat News.
- 1 2 "Keynote by Stephen Lewis delivered at the 21st Annual Conference of The Union - North America Region, Vancouver, Canada, February 24, 2017" (PDF).